Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  16 (2024)
Volume  15 (2023)
Volume  14 (2022)
Volume  13 (2021)
Volume  12 (2020)
Volume  11 (2019)
Volume  10 (2018)
Volume  9 (2017)
Volume  8 (2016)
Volume  7 (2015)
Volume  6 (2014)
Volume  5 (2013)
Volume  4 (2012)
Volume  3 (2011)
Volume  2 (2010)
Volume  1 (2009)
Related articles

VOLUME 16 , ISSUE S2 ( August, 2024 ) > List of Articles

RESEARCH ARTICLE

Follow-up of Babies Born after Treatment with Aromatase Inhibitor, an Off-label Ovulation-inducing Agent

Mosammat Rashida Begum, Nazia Ehsan, Mariya Ehsan, Imran Hossain, Azaz B Sharif, Ehsan Quadir

Keywords : Anovulation, Clomiphene citrate, Congenital anomaly, Letrozole

Citation Information :

DOI: 10.5005/jp-journals-10006-2476

License: CC BY-NC 4.0

Published Online: 02-09-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Background: Anovulation is the leading cause of infertility. Among causes of anovulation, polycystic ovarian syndrome (PCOS) is the prime one. Ovulation induction (OI) is the most common mode of treatment for anovulatory infertility. Clomiphene citrate (CC) has been used as a first-line drug for ovulation induction for a long back. Letrozole, an aromatase inhibitor (AI), is now a widely used ovulation-inducing agent because of the lack of antiestrogenic side effects, which is a significant concern in CC. Different studies reported congenital abnormalities in babies born with letrozole use. Any search instrument has not seen studies on developmental milestone delays in babies born by letrozole use. Objective: The purpose of the study was to follow-up on the growth and developmental milestones of babies born after treatment with AI, an off-labeled OI drug. Materials and methods: This cohort study was conducted in the infertility care and research center (ICRC), Dhaka, Bangladesh. A total of 1,895 babies were recruited in this study. Among them, 1,059 babies were in the “study group” who were born by OI with letrozole and 836 were in the “control group” who were born spontaneously. The main outcome measures were postnatal growth and developmental milestones of the babies born using letrozole as OI. Others are congenital abnormalities, birth weight, and birth asphyxia. A p-value < 0.05 was considered significant. Results: Gestational age, birth weight, and birth defect rate were similar in both groups. The height and weight of the babies in both groups were compared to observe whether there was any developmental delay in babies born by letrozole, and it was not significant between the study and control groups. Physical, mental, and cognitive development of babies were assessed according to CDC criteria; the difference between the two groups is not statistically significant. There was a milestone developmental delay in 3.12% of babies in the letrozole group and 3.83% of babies in the spontaneous group. Three babies (0.28%) had delayed mental development due to autism in the letrozole group, and 2 (0.24%) in the spontaneous group. However, the difference is not statistically significant. Conclusion: According to the study's results, there does not appear to be a higher risk of congenital anomalies, postnatal growth retardation, or developmental delay in babies of women who received letrozole as OI compared to spontaneous pregnancies.

PDF Share
  1. Gonen Y, Casper RF. Sonographic determination of an adverse effect of clomiphene citrate on endometrial growth. Hum Reprod 1990;5(6):670–674. DOI: 10.1093/oxfordjournals.humrep.a137165.
  2. Nelson LM, Hershlag A, Kurl RS, et al. Clomiphene citrate directly impairs endometrial receptivity in the mouse. Fertil Steril 1990;53(4):727–731. PMID: 2318331.
  3. Li TC, Warren MA, Murphy C, et al. A prospective, randomised, cross-over study comparing the effects of clomiphene citrate and cyclofenil on endometrial morphology in the luteal phase of normal fertile women. Br J Obstet Gynaecol 1992;999(12):1008–1013. DOI: 10.1111/j.1471-0528.1992.tb13708.x.
  4. Franks S, Adams J, Mason H, et al. Ovulatory disorders in women with polycystic ovary syndrome. Clin Obstet Gynaecol 1985;12(3):605–632. PMID: 3933789.
  5. Hull MGR. The causes of infertility and relative effectiveness of treatment. In: Templeton AA, Drife JO Infertility. London; Springer-Verlag 1992:33–62.
  6. Garcia J, Jones GS, Wentz AC. The use of clomiphene citrate. Fertil Steril 1977;28(7):707–717. DOI: 10.1016/s0015-0282(16)42670-1.
  7. Gysler M, March C, Mishell DJ Jr, et al. A decade's experience with an individualised clomiphene treatment regimen including its effects on the postcoital test. Fertil Steril 1982;37(2):161–167. DOI: 10.1016/s0015-0282(16)46033-4.
  8. Mikkelson TJ, Kroboth PD, Cameron WJ, et al. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertil Steril 1986;46(3):392–396. DOI: 10.1016/s0015-0282(16)49574-9.
  9. Hsu CC, Kuo HC, Wang ST, et al. Interference with uterine blood flow by clomiphene citrate in women with unexplained infertility. Obstet Gynecol 1995;86(6):917–921. DOI: 10.1016/0029-7844(95)00287-2.
  10. Homburg R. Clomiphene citrate—end of an era? A mini-review. Hum Reprod 2005;20(8): 2043–2051. DOI: 10.1093/humrep/dei042.
  11. Kamphuis EI, Bhattacharya S, van der Veen F, et al. Evidence based IVF group. Are we overusing IVF? BMJ 2014;348:g252. DOI: 10.1136/bmj.g252.
  12. Mitwally MFM, Casper RF. Aromatase inhibition: A novel method of ovulation induction in women with polycystic ovarian syndrome. Reprod Technol 2000;10:244–247. Available from: https://www.researchgate.net/publication/281549099_Aromatase_Inhibition_A_novel_method_of_ovulation_induction_in_women_with_polycystic_ovary_syndrome.
  13. Mitwally M FM, Casper RF. The aromatase inhibitor, letrozole: A promising alternative for clomiphene citrate for induction of ovulation. Fertil Steril 2000;74(suppl 1):S35. DOI: 10.1016/S0015-0282(00)00814-1.
  14. Mitwally MFM, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001;759(2):305–309. DOI: 10.1016/s0015-0282(00)01705-2.
  15. Fisher SA, Reid RL, VAN Vugt DA, et al. A randomized, double-blind comparison of the effect of clomiphene citrate and the AI letrozole on ovulatory function in normal women. Fertil Steril 2002;78:280–285. DOI: 10.1016/s0015-0282(02)03241-7.
  16. Mitwally MFM, Casper RF. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil Steril 2002;77(4):776–780. DOI: 10.1016/s0015-0282(01)03280-0.
  17. Mitwally MF, Casper RF. Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum Reprod 2003;18(8):1588–1597. DOI: 10.1093/humrep/deg311.
  18. Mitwally MF, Casper RF. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J Soc Gynecol Investig 2004;11(6):406–415. DOI: 10.1016/j.jsgi.2004.03.006.
  19. Rosenfeld C R, Roy T, Cox BE. Mechanisms modulating estrogen-induced uterine vasodilation. Vascul Pharmacol 2002;38(2):115–125. DOI: 10.1016/s0306-3623(02)00135-0.
  20. Tatsumi T, Jwa SC, Kuwahara A, et al. Pregnancy and neonatal outcomes following letrozole use in frozen-thawed single embryo transfer cycles. Hum Reprod 2017;32(6):1244–1248. DOI: 10.1093/humrep/dex066.
  21. Amer SA, Smith J, Mahran A, et al. Double-blind randomized controlled trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian syndrome. Hum Reprod 2017;32(8):1631–1638. DOI: 10.1093/humrep/dex227.
  22. Roy KK, Baruah J, Singla S, et al. A prospective randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. J Hum Reprod Sci 2012;5(1):20–25. DOI: 10.4103/0974-1208.97789.
  23. Eskew A, Bedrick B, Hardi A, et al. Letrozole versus clomiphene citrate for unexplained infertility: A systematic review and meta-analysis of a randomised controlled trial. Fertil Steril 2018;110(4): Supplement E248. DOI: 10.1111/jog.12393.
  24. Casper RF, Mitwally MF. Review: Aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 2006;91(3):760–771. DOI: 10.1210/jc.2005-1923.
  25. Biljan MM, Hemmings R, Brassard N. The outcome of 150 babies following treatment with letrozole or letrozole and gonadotropins. Fertility and Sterility 2005;84 Suppl 1:S95. DOI: 10.1016/j.fertnstert.2005.07.230.
  26. Kar S. Current evidence supporting ‘letrozole’ for ovulation induction. J Hum Reprod Sci 2013;6(2):93–98. DOI: 10.4103/0974-1208.117166.
  27. Tulandi T, Martin J, Al-Fadhli R, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 2006;85(6):1761–1765. DOI: 10.1016/j.fertnstert.2006.03.014.
  28. Novartis Pharmaceuticals Canada Inc. Health Canada Endorsed Important Safety Information on Femara (letrozole). 2005, 1–3.
  29. Requena A, Herrero J, Landeras J, et al. Use of letrozole in assisted reproduction: A systematic review and meta-analysis. Hum Reprod Update 2008;14:571–582. DOI: 10.1093/humupd/dmn033.
  30. Diamond M, Legro R, Coutifiaris C, et al. Letrozole, gonadotropin, or clomiphene for unexplained infertility. N Engl J Med 2015;373(13):1230–1240. DOI: 10.1056/NEJMoa1414827.
  31. Bryan SM, Hindmarsh PC. Normal and abnormal fetal growth. Horm Res 2006;65(Suppl 3):19–27. DOI: 10.1159/000091502.
  32. Forman R, Gil S, Moretti M, et al. Fetal safety of letrozole and clomiphene citrate for ovulation induction. J Obstet Gynaecol Can 2007;29(8):668–671. DOI: 10.1016/s1701-2163(16)32551-8.
  33. Gill SK, Moretti M, Koren G. Is the use of letrozole to induce ovulation teratogenic? Can Fam Physician 2008;54(3):353–354. PMID: 18337526.
  34. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014;371(2):119–129. DOI: 10.1056/NEJMoa1313517.
  35. Badawy A, Shokeir T, Allam AF, et al. Pregnancy outcome after ovulation induction with aromatase inhibitors or clomiphene citrate in unexplained infertility. Acta Obstet Gynecol Scand 2009;88:187–191. DOI: 10.1111/aogs.14195.
  36. Sharma S, Ghosh S, Singh S, et al. Congenital malformations among babies born following Letrozole or clomiphene for infertility treatment. PLoS One 2014;9(10):e108219. DOI: 10.1371/journal.pone.0108219.
  37. Sene AA, Ghorbani S, Ashrafi M. Comparison of the pregnancy outcomes and the incidence of fetal congenital abnormalities in infertile women treated with letrozole and clomiphene citrate. J Obstet Gynaecol Res 2018;44(6):1036–1041. DOI: 10.1111/jog.13644.
  38. Pundir J, Achilli C, Bhide P, et al. Risk of foetal harm with letrozole use in fertility treatment: A systematic review and meta-analysis. Hum Reprod Update 2021;27(3):474–485. DOI: 10.1093/humupd/dmaa055.
  39. Takeshima K, Ezoe K, Kawasaki N, et al. Perinatal outcomes and congenital anomalies associated with letrozole and natural cycles in single fresh cleaved embryo transfers: A single-center, 10-year cohort study. F S Rep 2022;3(2):138–144. DOI: 10.1016/j.xfre.2022.03.001.
  40. Farquhar C, Marjoribanks J. Assisted reproductive technology: An overview of Cochrane reviews. Cochrane Database Syst Rev 2018;8(8):CD010537. DOI: 10.1002/14651858.CD010537.pub5.
  41. Al Wattar BH, Teede H, Garad R, et al. Harmonising research outcomes for polycystic ovary syndrome: An international multi-stakeholder core outcome set. Hum Reprod 2020;35(2):404–412. DOI: 10.1093/humrep/dez272.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.